Inhibition of IkB kinase and NF-kappaB by a novel synthetic compound SK 2009

Related Experiment Video

Updated: Jun 18, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Ravi Kumar Anchoori1, Kuzhuvelil B Harikumar, Venkateswara Rao Batchu

  • 1Division of Chemical Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

Bioorganic & Medicinal Chemistry
|December 8, 2009
PubMed

Insights

Novel compound SK2009 effectively inhibits nuclear factor-kappa B (NF-kappaB) activation in leukemic cells. This finding suggests SK2009

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • Nuclear factor-kappa B (NF-kappaB) is crucial for cell survival in immune and inflammatory responses.
  • Deregulated NF-kappaB activity is common in human cancers, contributing to treatment resistance.
  • Simplactone analogs are being investigated for their potential therapeutic effects.

Purpose of the Study:

  • To evaluate novel simplactone analogs for their ability to inhibit IkB kinase and NF-kappaB activity.
  • To identify potent inhibitors of NF-kappaB activation in cancer cells.

Main Methods:

  • Screening of six novel compounds for inhibition of tumor necrosis factor (TNF)-induced NF-kappaB activity.
  • Characterization of the most potent compound, SK2009, in KBM-5 leukemic cells.
  • Assessment of SK2009's effects on IkappaBalpha kinase activation and NF-kappaB-dependent gene expression.

Main Results:

  • Compound SK2009 demonstrated the highest potency in suppressing TNF-induced NF-kappaB activation in KBM-5 leukemic cells.
  • SK2009 was found to suppress TNF-induced IkappaBalpha kinase activation.
  • SK2009 inhibited the expression of NF-kappaB-dependent genes: cyclin D1, Bcl-2, and VEGF.

Conclusions:

  • SK2009 is a potent inhibitor of NF-kappaB signaling.
  • The findings suggest SK2009's potential as an anticancer agent by targeting NF-kappaB pathways.
  • Further research into SK2009 is warranted for its therapeutic application in cancers with deregulated NF-kappaB.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...